Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSV | O60911 | 2/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.37 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24448852 | 0.86 | CTSV (0.51) | CTSVCTSLCHRNA7ALDH1A1 | |
| SCHEMBL24449358 | 0.82 | CTSV (0.42) | CTSVCTSLFFAR1CHRNA7ALDH1A1 | |
| SCHEMBL24448850 | 0.80 | ALOX5 (0.51) | CTSVCTSLFFAR1MAOB | |
| SCHEMBL14112764 | 0.73 | ALOX5AP (0.49) | MAOBCHRNA7PDGFRBPDGFRAALDH1A1 | |
| SCHEMBL17821822 | 0.72 | MEN1 (0.52) | CTSVCTSLCHRNA7ALDH1A1 | |
| SCHEMBL25946416 | 0.72 | MRGPRX4 (0.51) | FFAR1MRGPRX4 | |
| SCHEMBL17481249 | 0.72 | ALOX5 (0.51) | CTSVCTSLMAOBMRGPRX4 | |
| SCHEMBL15365 | 0.71 | MAOB (0.58) | FFAR1MAOBPDGFRBPDGFRAMRGPRX4 | |
| SCHEMBL17821658 | 0.69 | HPGD (0.53) | CTSVCTSLCHRNA7ALDH1A1 | |
| SCHEMBL4970541 | 0.69 | CTSV (0.53) | CTSVCTSLCHRNA7ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | Epizyme, Inc. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162197-A1 | MYST FAMILY HISTONE ACETYLTRANSFERASE INHIBITORS | EP300, KAT2A, KAT6A | CTSV 2536/4885CTSL 3658/4885FFAR1 4045/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.